SOURCE: The Life Sciences Report

The Life Sciences Report

October 29, 2015 09:00 ET

Aethlon Medical's James Joyce Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - October 29, 2015) - Aethlon Medical Inc. (NASDAQ: AEMD) has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James "Jim" Joyce tells The Life Sciences Report how this device is helping transform modern healthcare.

The Life Sciences Report: Aethlon Medical Inc. has developed a novel affinity biofiltration platform that removes disease-enabling particles from the bloodstream. How effective is it, and what makes it so effective?

James Joyce: At Aethlon Medical, we have established an expansive therapeutic platform that allows us to target a wide range of disease-promoting targets from the circulatory system. Our lead product, the Aethlon Hemopurifier, provides a clinical pathway into infectious disease and cancer. In 2014, TIME magazine named the device one of the 25 best inventions of the year and also one of the 11 most remarkable advances in healthcare.

In the case of the Hemopurifier, our device integrates advanced plasma membrane technology with an affinity lectin to reduce the presence of infectious disease and oncology targets without stripping out essential components required for health. The Hemopurifier is designed for…

Continue reading this interview: Aethlon Medical's Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Aethlon Medical Inc. is a sponsor of Streetwise Reports. Mr. Joyce had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Joyce and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Contact Information